alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 201–225 of 1,385 studies (page 9 of 56) · 28,180 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Showing 1,385 studies tagged amyloid-beta — clear

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 13,658 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Meat Consumption and Cognitive Health by APOE Genotype

✓ Peer-reviewed alzhub usefulness score 59 out of 100. JAMA Network Open 2026-03-19

Among 2157 older adults without dementia (mean [SD] age 71.2 [9.2] years; 1337 female [62.0%]), 1680 participants had longitudinal cognition data and 569 participants (26.4%) had APOE34/44 genotypes. 5 key findings →

Design: cohort study Participants: 1,680 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Natural compounds as multitarget agents in Alzheimer's diseases: evidence from in vivo and in vitro models

✓ Peer-reviewed alzhub usefulness score 59 out of 100. Frontiers in pharmacology 2026-02-23

Overall, the available evidence suggests that natural compounds confer multitarget neuroprotective effects that directly engage with key pathological mechanisms underlying AD. 4 key findings →

Design: systematic review Participants: 41 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene

✓ Peer-reviewed alzhub usefulness score 59 out of 100. Nature 1995-08-01

The study reported the cloning of a novel gene (E5-1) encoded on chromosome 1 with sequence similarity to the S182 gene on chromosome 14q24.3. 5 key findings →

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Modulating heart rate oscillation affects plasma amyloid beta and tau levels in younger and older adults

✓ Peer-reviewed alzhub usefulness score 59 out of 100. Scientific reports 2023-03-09

Slow paced breathing via heart rate variability (HRV) biofeedback stimulates vagus-nerve pathways that counter noradrenergic stress and arousal pathways that can influence production and clearance of Alzheimer's disease (AD)-related proteins. 2 key findings →

Participants: 108 Evidence: high

Full summary, score breakdown and related studies → Original source

Serum amyloid beta protein in young and elderly depression: a pilot study

✓ Peer-reviewed alzhub usefulness score 59 out of 100. Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society 2009-12-01

Serum Abeta40/42 ratio was significantly higher in MDD patients than in controls, and this difference was seen for both elderly and young subjects. 5 key findings →

Design: cohort study Participants: 60 Evidence: moderate

Full summary, score breakdown and related studies → Original source

Association of Dipeptidyl Peptidase-4 Inhibitor Use and Amyloid Burden in Patients With Diabetes and AD-Related Cognitive Impairment

✓ Peer-reviewed alzhub usefulness score 58 out of 100. Neurology 2021-08-11

These findings suggest that DPP-4i use is associated with low amyloid burden and favorable long-term cognitive outcome in diabetic patients with ADCI. 2 key findings →

Design: longitudinal study Participants: 70 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease

✓ Peer-reviewed alzhub usefulness score 58 out of 100. Proceedings of the National Academy of Sciences of the United States of America 1993-03-01

Apolipoprotein E is immunochemically localized to the senile plaques, vascular amyloid, and neurofibrillary tangles of Alzheimer disease. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease

✓ Peer-reviewed alzhub usefulness score 58 out of 100. Annals of internal medicine 2002-08-01

The association between the apoE epsilon4 allele and Alzheimer disease does not seem to be mediated by vascular factors. 1 key finding →

Participants: 1,449 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Sex, amyloid, and APOE ε4 and risk of cognitive decline in preclinical Alzheimer's disease: Findings from three well-characterized cohorts

✓ Peer-reviewed alzhub usefulness score 58 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2018-05-24

Although Aβ did not differ by sex, cognitive decline was greater in females with higher Aβ. 3 key findings →

Participants: 755 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The apolipoprotein E epsilon 4 allele and decline in different cognitive systems during a 6-year period

✓ Peer-reviewed alzhub usefulness score 58 out of 100. Archives of neurology 2002-07-01

The presence of epsilon 4 was associated with risk of developing AD on follow-up (relative risk, 1.92; 95% confidence interval, 1.27-2.89). 3 key findings →

Design: cohort study Participants: 624 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Posterior cingulate glucose metabolism, hippocampal glucose metabolism, and hippocampal volume in cognitively normal, late-middle-aged persons at 3 levels of genetic risk for Alzheimer disease

✓ Peer-reviewed alzhub usefulness score 58 out of 100. JAMA neurology 2013-03-01

Although there were no significant differences among the 3 groups of participants in their clinical ratings, neuropsychological test scores, hippocampal volumes (P = .60), or hippocampal glucose metabolism measurements (P = .12), there were significant group differences in their posterior cingulate glucose metabolism measurements (P = .001). 2 key findings →

Design: cross-sectional Participants: 31 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Rare coding mutations identified by sequencing of Alzheimer disease genome-wide association studies loci

✓ Peer-reviewed alzhub usefulness score 58 out of 100. Annals of neurology 2015-07-28

Targeted sequencing of confirmed GWAS loci revealed an excess burden of deleterious coding mutations in LOAD, with the greatest burden observed in ABCA7 and BIN1. 4 key findings →

Participants: 176 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Association between apolipoprotein E genotype and Alzheimer disease in African American subjects

✓ Peer-reviewed alzhub usefulness score 58 out of 100. Archives of neurology 2002-04-01

Compared with individuals with the APOEepsilon3/epsilon3, the odds of having AD were significantly increased among those with 1 or more copies of the epsilon4 allele; the odds ratio (OR) for the epsilon3/epsilon4 genotype was 2.6 (95% confidence interval [CI], 1.8-3.7), and the OR for the epsilon4/epsilon4 genotype was 10.5 (95% CI, 5.1-21.8). 3 key findings →

Design: case-control study Participants: 338 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Personality factors moderate the associations between apolipoprotein genotype and cognitive function as well as late onset Alzheimer disease

✓ Peer-reviewed alzhub usefulness score 58 out of 100. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 2012-12-01

Phenotypic personality dimensions, primarily neuroticism and extraversion, moderate the relationship between APOE [Latin Small Letter Open E]-4 genotype and cognitive outcomes among older adults. 1 key finding →

Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Apolipoprotein E epsilon4 magnifies lifestyle risks for dementia: a population-based study

✓ Peer-reviewed alzhub usefulness score 58 out of 100. Journal of cellular and molecular medicine 2008-02-08

The risk of dementia and Alzheimer's disease (AD) probably results from an interaction between genetic and environmental factors. 3 key findings →

Participants: 1,449 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Sex differences in the association of the apolipoprotein E epsilon 4 allele with incidence of dementia, cognitive impairment, and decline

✓ Peer-reviewed alzhub usefulness score 58 out of 100. Neurobiology of aging 2010-07-08

We examined longitudinal associations between the apolipoprotein E ε4 allele (ApoE4(+) status) and several cognitive outcomes and tested effect modification by sex. 3 key findings →

Design: longitudinal study Participants: 113 Evidence: moderate

Full summary, score breakdown and related studies → Original source

APOE ε4 carriers share immune-related proteomic changes across neurodegenerative diseases

✓ Peer-reviewed alzhub usefulness score 58 out of 100. Nature medicine 2025-07-15

The APOE ε4 genetic variant is the strongest genetic risk factor for late-onset Alzheimer's disease (AD) and is increasingly being implicated in other neurodegenerative diseases. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

From across this tag

10 of the 1,383 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed